Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Novel rhThrombin Provided in Innovative Stabilized Formulation

Published: Friday, November 01, 2013
Last Updated: Friday, November 01, 2013
Bookmark and Share
Scil Proteins and LEUKOCARE develop a stabilized recombinant human thrombin manufactured in bacteria.

Scil Proteins GmbH and LEUKOCARE AG have announced results of their strategic partnership to develop a stabilized recombinant human thrombin (rhThrombin).

The new, proprietary and highly cost-effective bacterial manufacturing process of rhThrombin is a recent in-house development of Scil Proteins. This recombinant production process does not rely on bovine or human blood derivatives and can be scaled up easily to meet market demands.

Combining rhThrombin with a formulation of LEUKOCARE’s proprietary Stabilizing and Protecting Solutions (SPS) technology results in increased stability during storage at elevated temperatures as well as during terminal sterilization by irradiation. This offers various opportunities for novel formulations and advanced functionalized medical devices.

Controlling bleeding in surgery and avoiding blood loss during surgical intervention can be managed in several ways. One being the topical application of thrombin as a haemostatic agent.

Currently there are three types of thrombin available for use in humans: bovine thrombin, human purified thrombin and only one rhThrombin which is produced in chinese hamster ovary cells.

However, bovine thrombin holds the risk of anti-thrombin antibody production in patients. A main concern regarding the use of human purified thrombin is the risk of infectious agents like viruses and limited stability.

Recombinant products are usually free of infectious agents and impurities. Clinical studies with other available rhThrombin demonstrated comparable efficacy but significantly lower immunogenicity.

The substrate was safely applied in haemorrhage control in patients with or without pre-existing anti-bovine thrombin antibodies. Hence, products with rhThrombin may offer improved safety in clinical use.

The novel stabilized rhThrombin developed by Scil Proteins and LEUKOCARE may be used in different medical applications and medical devices to control bleeding for example sponges, glues, sealants or advanced wound dressings.

“We are able to provide access to high quality rhThrombin, free of blood derived components and with a fully scalable manufacturing process in bacteria” said Dr. Ulrike Fiedler, CEO of Scil Proteins.

Michael Scholl, CEO of LEUKOCARE added “As rhThrombin protected by our SPS technology is stable during irradiation it offers the opportunity for end sterilization as common in the medical device industry and as requested by regulatory agencies.”

Scil Proteins and LEUKOCARE are currently evaluating partners in the pharmaceutical and the medical device industry for the clinical development and commercialization of the stabilized rhThrombin.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
New Imaging Technique in Alzheimer’s Disease
Study confirms new imaging technique corresponds a higher degree of actual brain changes.
Ancient Eggshell Protein Breaks Through DNA Time Barrier
Fossil proteins from a 3.8million year-old eggshell have been identifed, suggests proteins could give insight into evolutionary tree.
New Weapon Against Hard-to-Treat Bacterial Infections
Using peptides, researchers have been able to prevent drug-resistance bacteria from forming abscesses.
Designing Drugs with a Whole New Toolbox
Researchers develop methods to design small, targeted proteins with shapes not found in nature.
Protein Studies Discover Molecular Secrets
Two protein studies have mapped proteins that reveal the secrets to recycling carbon and healing cells.
Tapping Evolution to Improve Biotech Products
Researchers show how 'ancestral sequence reconstruction' can be used to guide engineering of a blood clotting protein.
Death-or-Repair Switch Protein Identified
Researchers have identified a protein that plays a key role in the decision process of cell damage repair or cellular suicide.
Gene Deletion Reveals Cell Secrets
Researchers have deleted 174 genes in yeast to analyse the effect of individual gene deletion.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!